Initiation of an automated insulin delivery (AID) system improves glycemic control in children and adolescents with type 1 ...

Cipla to introduce Afrezza, an inhaled insulin for diabetes, offering convenience but not advised for lung-related concerns.

Imagine a world where diabetes could be treated with a simple pill that essentially reprograms your body to produce insulin ...

Objective, but not subjective, EDS was associated with insulin resistance and disordered glucose metabolism among patients with OSA.

Cipla has secured exclusive rights to distribute and market Afrezza, an inhalable insulin, in India. Developed by MannKind, ...

This is the first and only non- injectable insulin to be developed for patients of both type 1 and type 2 diabetes mellitus.

A study found that there is a significant association between the number of meals per day and the risk of developing insulin ...

Shares of MannKind Corporation climbed more than 2% in premarket trading Wednesday, on track to extend gains from the ...

At just 21 years old, recent Florida Atlantic University graduate Dylan Backer was rushed into the emergency room with a ...

Significant associations were seen for fasting, 30-minute and 120-minute plasma insulin and proinsulin with AS.

Cipla received approval from India's Central Drugs Standard Control Organisation to distribute and market Afrezza inhalation ...

Some patients with diabetes develop a serious condition known as diabetic cardiomyopathy, which is slow and cannot be directly attributed to hypertension or other cardiovascular disorders.